Description: Sernova Corp. is a development-stage regenerative medicine company. The Company is engaged in the development of its Cell Pouch and associated technologies, including therapeutic cells for the treatment of chronic diseases and local immune protection technologies. It is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted and prevascularized medical device (the Cell Pouch), protected from immune system attack. The Cell Pouch is designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the treatment of chronic diseases, such as diabetes and thyroid disease. Its lead program is the clinical development of the Cell Pouch for treatment of patients with insulin dependent diabetes. It is also evaluating Cell Pouch for the treatment of patients with hemophilia A.
Home Page: www.sernova.com
SVA Technical Analysis
The Stiller Centre
London,
ON
N6G 4X8
Canada
Phone:
519 858 5184
Officers
| Name | Title |
|---|---|
| Mr. Frank A. Holler MBA | Exec. Chairman |
| Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. | Pres, CEO & Director |
| Mr. David Swetlow C.A, C.A., CPA | Chief Financial Officer |
| Mr. Douglas Maret | Chief Science Officer |
| Mr. Christopher Barnes | VP of Investor Relations |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 13.9775 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |